Comparison · NCT02553317-e7be5c2c
Caplacizumab vs Placebo: Number and Percentage of Subjects With a Recurrence of TTP in the Overall Study Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Caplacizumab vs Placebo: Number and Percentage of Subjects With a Recurrence of TTP in the Overall Study Period. Trial comparisons, record NCT02553317-e7be5c2c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02553317-e7be5c2c
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.127 | 0.0681 | 0.224 | wilson | |
| Risk in group 2 | 0.384 | 0.281 | 0.498 | wilson | |
| Risk difference, group 1 minus group 2 | -0.257 | -0.386 | -0.115 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.33 | 0.168 | 0.65 | log | |
| Odds ratio, group 1 over group 2 | 0.233 | 0.1 | 0.542 | log | |
| Number needed to treat, for one fewer participant with the outcome on Caplacizumab than on Placebo | 3.89 | 2.59 | 8.67 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Caplacizumab | Caplacizumab 10 mg once daily | 9 | 71 | OG000 |
| Group 2 | Placebo | Placebo once daily | 28 | 73 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number and Percentage of Subjects With a Recurrence of TTP in the Overall Study Period
- Description
- Number and percentage of subjects with a recurrence of TTP during the Overall Study Period (i.e., including follow-up \[FU\]) (i.e., second key secondary endpoint).
- Time frame
- The overall study period (covers both the overall treatment period and the follow-up period), a median (min, max) of 65 (2, 110) days.
- Population
- ITT Population (for the respective study period, i.e., overall study period)
Source ClinicalTrials.gov
Trial
- Title
- Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
- NCT number
- NCT02553317
- Phases
- PHASE3
- Conditions
- Acquired Thrombotic Thrombocytopenic Purpura
- Interventions
- Caplacizumab, Placebo
- Lead sponsor
- Ablynx, a Sanofi company
- Results first posted
- 2019-05-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02553317?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02553317-e7be5c2c